BIO

NEUTRALM&A

Bio-Rad Laboratories, Inc.

2026-09-24

Price

$387.54

+2.29%

This is the 2026-09-24 snapshot — the signals and analysis for BIO as of this single trading day.

View full BIO research hub →

Score12.5Top Tier

Signals4/8 DNA3/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume1.4xvs 20d avg

Analysis

Bio-Rad (BIO) is demonstrating High-Conviction Price Discovery as it absorbs recent negative valuation commentary and pushes higher, supported by a PERFECT_STACK and BOLLINGER_SQUEEZE. The breakout is fundamentally driven by management's updated M&A playbook and profitable growth strategy unveiled at today's Bernstein Healthcare Forum. In a RISK_ON macro regime characterized by flush liquidity and exceptionally tight credit spreads, institutional buyers are confidently looking past short-term life science market headwinds to quietly accumulate shares.

Fired Signals

GOLDEN CROSSBOLLINGER SQUEEZEMARKET LEADERPERFECT STACKQUIET ACCUMULATIONSMA BOUNCEINSIDE OUTDISTRIBUTION

Key Takeaways

Actionable Thesis: The convergence of QUIET_ACCUMULATION, a BOLLINGER_SQUEEZE, and a well-received M&A strategy update signals a high-probability upward breakout.
Key Risk: Continued softness in the broader life science tools sector could weigh on top-line revenue if the new M&A playbook takes time to scale.
What to Watch: Monitor follow-through volume above recent highs to confirm the squeeze is resolving upward, which would thoroughly invalidate recent overvaluation claims.

← Back to 2026-09-24 View Full BIO History →Yahoo Finance &nearr;